Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2026)

Revolution Medicines has reported Accumulated Depreciation for 8 years, with the latest figure at $30.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 31.22% year-over-year to $30.7 million; the trailing twelve-month figure through Mar 2026 stood at $30.7 million (up 31.22% YoY), and the FY2025 full-year result was $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $30.7 million, up from $28.5 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $30.7 million in Q1 2026, with the low at $11.6 million in Q1 2022.
• Average Accumulated Depreciation over 5 years is $19.9 million, with a median of $18.9 million recorded in 2024.
• Year-over-year, Accumulated Depreciation soared 35.59% in 2023 and climbed 19.86% in 2024.
• Tracing RVMD's Accumulated Depreciation over 5 years: stood at $14.5 million in 2022, then advanced by 22.12% to $17.7 million in 2023, then climbed by 23.34% to $21.8 million in 2024, then jumped by 30.66% to $28.5 million in 2025, then climbed by 7.6% to $30.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $30.7 million (Q1 2026), $28.5 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.

Peer Comparison